AS-1763 is under clinical development by Carna Biosciences and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AS-1763’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AS-1763 overview
AS-1763 (CB-1763) is under development for the treatment of B-cell lymphoma, chronic lymphocytic leukemia (CLL), mantle cell lymphoma, relapsed and refractory chronic lymphocytic leukemia, follicular lymphoma, marginal zone lymphoma, diffuse large B-cell lymphoma, Richter syndrome and Walden's macroglobulinemia, small lymphocytic lymphoma, B-cell non-Hodgkin lymphoma. The drug candidate is administered through oral route in the form of tablet. It acts by targeting Bruton’s tyrosine kinase (BTK) inhibitor.
See Also:
Carna Biosciences overview
Carna Biosciences (Carna) is a biotechnology company that discovers and develops drugs for the treatment of cancer and inflammatory diseases. The company offers products such as kinase proteins, biotinylated kinases, substrates, assay kits, protein substrates, inactive kinases, inactive-mutant kinases, pre-selected panels, crystal-grade proteins, and ready-to-use products to study kinases-molecule interactions, among others. Its kinase proteins include cytoplasmic tyrosine kinases, receptor tyrosine kinases, lipid kinases, serine and threonine kinases, among others. Carna offers services such as RPPA cell signaling analysis service, tyrosine kinase cell-based assay, co-crystallography, assay development and profiling services. The company serves its clients across Japan. Carna is headquartered in Kobe, Japan.
For a complete picture of AS-1763’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
